CLINICAL_TRIALS
trial_result
· 2021-01-11
Clinical Trial Update: Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease [Phase 2]
Summary
Phase 2 clinical trial update on KPI-121 for inflammatory Meibomian Gland Disease (blepharitis) completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Kala Pharmaceuticals, Inc. | Conditions: Blepharitis | Phase 2 | Status: COMPLETED | Results posted: 2021-01-11